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Abstract
Background: Previous studies demonstrated Ganoderma lucidum polysaccharides (GL-PS), a form
of bioactive β-glucan can stimulate the maturation of monocyte-derived dendritic cells (DC). The
question of how leukemic cells especially in monocytic lineage respond to GL-PS stimuli remains
unclear.
Results: In this study, we used in vitro culture model with leukemic monocytic cell-lines THP-1 and
U937 as monocytic effectors cells for proliferation responses and DCs induction. We treated the
THP-1 and U937 cells with purified GL-PS (100 μg/mL) or GL-PS with GM-CSF/IL-4. GL-PS alone
induced proliferative response on both THP-1 and U937 cells but only THP-1 transformed into
typical DC morphology when stimulated with GL-PS plus GM-CSF/IL-4. The transformed THP-1
DCs had significant increase expression of HLA-DR, CD40, CD80 and CD86 though not as high
as the extent of normal monocyte-derived DCs. They had similar antigen-uptake ability as the
normal monocyte-derived DCs positive control. However, their potency in inducing allogeneic T
cell proliferation was also less than that of normal monocyte-derived DCs.
Conclusion: Our findings suggested that GL-PS could induce selected monocytic leukemic cell
differentiation into DCs with immuno-stimulatory function. The possible clinical impact of using this
commonly used medicinal mushroom in patients with monocytic leukemia (AML-M4 and M5)
deserved further investigation.
Background
In both Western and Oriental societies, cancer patients
commonly take complementary and alternative medicine
while they underwent conventional anti-cancer therapy
[1-3]. Among different kinds of alternative medicine,
herbal medicine is the most popular form taken by
patients in United Kingdom [4]. In our community, more
than 42% of our pediatric cancer patients took herbal
medicine when they received conventional chemotherapy
[5]. Among them, the commonest herb being used is the
extracts derived from Ganoderma lucidum.
Ganoderma lucidum (GL) is a traditional Chinese medicine
known by the layman as the "herb of immortality". It was
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used as a health tonic to promote longevity for more than
two thousands years. It has two major groups of bioactive
components: polysaccharides and triterpenes. In recent
decade, they have been extensively studied because of its
potential immunomodulating and anti-tumor effects as
demonstrated in both in vitro and in vivo models [6]. So
far, currently available data suggested that GL polysaccha-
rides exert anti-cancer functions indirectly by activation of
host's immune responses whereas GL triterpenes can kill
cancer cells directly via its direct cytotoxic effect [7]. GL
polysaccharides are purified from the mushroom myc-
elium and they contain branched β-glucan.
Dendritic cells (DCs) are the most potent antigen present-
ing cells and have unique ability in linking innate and
adaptive immunity. Due to the scarcity of circulating DCs,
the current protocol to study DCs biology and differentia-
tion is mainly through differentiation of monocytes to
DCs with the cytokines GM-CSF and IL-4. Recently, DCs
can be induced from acute myeloid leukemic cells (AML)
and this raised the possibility of using DCs derived from
autologous leukemic cells for therapeutic uses [8]. Several
AML cell-lines including monocytic THP-1, KG-1 and
CD34+ MUTZ3 cell-lines have been used as cellular mod-
els to study the differentiation of leukemic cells and DCs
biology. However, the differentiation protocols differed
greatly. For example, mature DCs could only be derived
from THP-1 and KG-1 by adding GM-CSF and IL-4
together with ionomycin and TNF-α [8]. Interestingly, all
study agreed that there is impaired response of leukemic
DC to LPS directed DCs maturation [9]. This suggested
that these leukemic DCs are somehow defective in
response to maturation stimuli.
We and other groups demonstrated GL mycelium polysac-
charides have the ability to stimulate the maturation of
human DCs [10-12]. While most reports advocating the
immunomodulating role of GL on normal monocytic
cells, our data provided a novel observation that GL
polysaccharides may also enhance monocytic leukemic
cells proliferation and induce dendritic cells differentia-
tion from monocytic leukemic blasts. The awareness of
such phenomenon may help us to design specific treat-
ment approach for monocytic leukemia.
Results
Cell proliferation response of THP-1 after GL 
polysaccharides stimulation
To relay the GL-PS has effect on leukemic cells, we evalu-
ated the effect of GL polysaccharides (GL-PS) on the acute
myeloid leukemia (AML) cell-lines THP-1 and U937 by
cell proliferation assay. GL-PS alone at the dose of 100 μg/
mL could stimulate the growth of both THP-1 and U937
cells. The average increases after the three-day exposure in
THP-1 and U937 cells were 1.53-fold and 1.16-fold higher
than the untreated control, respectively (Fig. 1A). Vincris-
tine, a chemotherapeutic drug, was used as control to
show the cells were responding. The cell cycle analysis
with PI staining showed that GL-PS did not induce S
phase arrest during the three-day treatments (Fig. 1B). By
checking the expression of proliferating cell nuclear anti-
gen (PCNA), which is an S-phase marker, both THP-1 and
U937 cells showed increases in PCNA expression after GL-
PS treatment (Fig. 1C).
Induction of DCs-like morphology and phenotype in GL-PS 
treated THP-1 cells
Under GL-PS treatment (100 μg/mL was used in all exper-
iments onwards), we observed DC-like morphology in
THP-1 cell culture. Since reports suggest that THP-1 can be
induced into DC by a combination of cytokines [8,13], we
hypothesized that GL-PS might also induce or enhance
the differentiation of THP-1 cells into THP-1 DCs. We cul-
tured these cells in the presence of GM-CSF/IL-4 with or
without GL-PS. We used Mo-DCs as positive control and
untreated THP-1 cells as negative control. THP-1 treated
with GL-PS plus GM-CSF/IL-4 yielded atypical large
adherent and elongated cells with multiple cytoplasmic
spikes (white arrow) comparing to the round floating
THP-1 cells and typical Mo-DCs with multiple satellite-
like cytoplasmic protrusions (Fig. 2A). Under the forward
and side scatter analysis of flow cytometry (lower panel),
we found that the THP-1 DCs derived with GL-PS (GL-PS
THP-1 DCs) had larger size as if the monocytes when dif-
ferentiated into DCs. For U937 cells, we did not observe
similar morphological changes (data not shown).
Phenotypic maturation of THP-1 DCs derived with GL-PS
We then checked the surface expression of antigen presen-
tation molecules and costimulation molecules, which
Mo-DCs normally express. In Fig. 2B, we found that the
THP-1 expressed relatively low levels of CD11c, HLA-DR,
CD40, CD80 and CD86 when compared with normal
Mo-DCs. Challenge of THP-1 with GM-CSF/IL-4 and GL-
PS demonstrated increase in all markers when it was com-
pared with the untreated THP-1 cells. To check the exper-
imental consistency, we then normalized the fluorescence
intensity from four experiments using the CD marker
expression in THP-1 cells alone as the 100% (Fig. 2C). GL-
PS alone could induce significant increase in CD11c,
HLA-DR and CD40 when compared with the negative
control THP-1 cells alone. But together with cytokine, the
GL-PS THP-1 DCs showed significant increase in all five
CD marker expressions, suggesting phenotypic maturity.
The GM-CSF/IL-4 alone did not always increase the matu-
ration marker expression in THP-1. To show the specifi-
city of DC differentiation in THP-1 cells, we repeated the
experiments on U937 cells. However, there was no signif-
icant increase in all DCs maturation markers (data not
shown).Journal of Hematology & Oncology 2008, 1:9 http://www.jhoonline.org/content/1/1/9
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(A) Leukemic cell proliferation induced by GL polysaccharides Figure 1
(A) Leukemic cell proliferation induced by GL polysaccharides. The time-response curves for the effect of GL 
polysaccharides (GL-PS, -▪-) at 100 μg/mL and vincristine (--) at 0.1 μM on THP-1 (Left panel) and U937 cells (right panel) 
determined by XTT cell proliferation assay. The results represent the mean ± SD of triplicate cultures of three representative 
experiments. *p < 0.05; ** p < 0.01; ***p < 0.001 versus negative control (-•-). (B) Cell cycle analysis with PI staining. The THP-
1 (left panel) and U937 cells (right panel) were treated with or without 100 μg/mL GL-PS for three days. The cell cycle analysis 
was then analyzed with PI staining and Cylchred Version 1.0.2 (Cardiff University, Wales, UK). The results shown were from 
one representative experiment of three independent experiments performed. (C) PCNA expression of GL-PS treated THP-1 
(upper panel) and U937 cells (lower panel) in three-day incubation. The results shown were from one representative experi-
ment of three independent experiments performed.
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Dendritic cell-like phenotype of THP-1 induced by GL-PS and GM-CSF/IL-4 Figure 2
Dendritic cell-like phenotype of THP-1 induced by GL-PS and GM-CSF/IL-4. (A) Microscopic morphology of normal 
mature monocyte-derived DCs (Mo-mDCs) and THP-1 DCs (upper panel). The round THP-1 cells changed to be adherent 
flatten cells (white arrows). Under forward scatter and side scatter analysis of flow cytometer (lower panel), the THP-1 DCs 
increased in size when compared with THP-1 cells alone. (B) Surface expression of antigen presentation and costimulation 
molecules on immature Mo-DCs (Mo-iDCs), THP-1 cells alone, THP-1 stimulated with GM-CSF/IL-4; GL-PS treated THP-1, 
THP-1 stimulated with both GL-PS and GM-CSF/IL-4. The expressions of DC maturation markers CD11c, HLA-DR, CD40, 
CD80 and CD86 on DCs were analyzed by flow cytometer after five-day differentiation. The results shown were from one 
representative experiment of triplicate independent experiments performed. (C) The average relative expression of the DC 
maturation markers. The results were presented as mean ± SD of three representative experiments. *p < 0.05; ** p < 0.01; 
***p < 0.001 versus that of THP-1 cells.
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Loss of cell proliferation response after added with 
cytokines
To show the differentiation commitment of the GL-PS
treated THP-1 cells in the presence of GM-CSF/IL-4, we
added GM-CSF/IL-4 to the THP-1 cells, which had been
treated with GL-PS for three days. We monitored the cell
growth for two more days (Day 4 and 5) by XTT prolifer-
ation assays (Fig. 3A). Adding GM-CSF/IL-4 induced sig-
nificant increase in proliferation in GL-PS treated THP-1
on Day 4. However, the proliferation became static after
Day 5. We confirmed the cell proliferation results with cell
counting using trypan blue exclusion assay. As shown in
Fig. 3B, we recorded significant increase in cell number
when either GM-CSF/IL-4 or GL-PS was added to the THP-
1 cells on Day 5. When both GL-PS and GM-CSF/IL-4
were added, the cell number retained similar to the nega-
tive untreated THP-1. The decrease was not due to the cell
death as indicated by the trypan blue staining (data not
shown).
Upregulated endocytotic activity of THP-1 DCs derived 
with GL-PS
We examined the endocytotic activity of the THP-1 DCs
using fluorescent labeled FITC-dextran as antigens and
incubated them at 37°C. We used PBS as negative control
as well as parallel experiments at 4°C to serve as the back-
ground fluorescence. We found that the THP-1, THP-1
DCs with GM-CSF/IL-4 and THP-1 with GL-PS showed
similar antigen uptake ability (Fig. 4A). For the GL-PS
THP-1 DCs, we unexpectedly found that there was an
increase in antigen uptake signals from the FITC-dextran
after normalizing with the negative control (Fig. 4B). In
order to rule out the possibility of upregulation of man-
nose receptor, which could account for the uptake of
FITC-dextran, we determined the expression level of man-
nose-receptor and we found no change was observed
(data not shown).
Low IL-12 and IL-10 production in THP-1 DCs derived with 
GL-PS
We detected low amount of IL-12 production from THP-1
cells, THP-1 DCs with GM-CSF/IL-4, THP-1 with GL-PS
and GL-PS THP-1 DCs (Fig. 5A). Though THP-1 DCs with
or without GL-PS had relatively higher IL-12 production,
the amount was not significant. In contrast, GL-PS THP-1
DCs showed significant increase in IL-10 production (Fig.
5B).
Decrease in T cell proliferation in allogeneic mixed 
lymphocyte reaction
We determined the outcome of those THP-1 DCs when
they were co-cultured with normal CD3+ T cells, with
immature and mature Mo-DCs as positive control. Signif-
icant increase in T cell proliferation was induced from
immature to mature DCs (Fig. 6A, left). Interestingly, we
found that there was a suppression of T cell proliferation
in the co-culture of GL-PS THP-1 DCs when compared
with other THP-1 cells or THP-1 DCs (Fig. 6A, left). When
compared with THP-1 cells alone, the GL-PS THP-1 DCs
showed significant decrease in T cell proliferation (Fig.
6A, right). We then examined that the suppression of T
cell proliferation was not due to the induction of apopto-
sis (data not shown). The suppression did not focus on
the CD4+ helper T cells and CD8+ cytotoxic T cells indi-
cated by no significant change in CD4/CD8+ ratio (Fig.
6B).
Discussion
We demonstrated herein that purified immunomodula-
tory GL polysaccharides, which have been widely used as
adjuvant therapy for anti-tumor purposes, could induce
both monocytic leukemic cell proliferation and abnormal
cellular differentiation in the form of immunoregulatory
DCs. Interestingly, such proliferative stimulation was not
found in other non-monocytic lymphoid and myeloid
leukemic cell lines tested (data not shown), suggesting
such effect was lineage specific. We also explored the pos-
sibility of using GL-PS to induce DCs from autologous
blast cells in order to reduce leukemic cell burden.
We found that even among monocytic leukemic cells
THP-1 and U937, there was a differential response to GL-
PS. GL-PS only enhanced proliferation of U937, an AML
M5 cell-line but could not induce its differentiation into
DCs as in THP-1. Contrary to our findings, GL polysaccha-
rides were reported to have to ability in inhibiting the
growth of U937 cells, but it was under the influence of a
conditioned medium primed by GL polysaccharides-stim-
ulated human blood mononuclear cells [14]. This finding
in fact suggested such inhibition required possible soluble
factors secreted by the primed monocytes. In a recent
report by Muller et al [15], GL was also demonstrated to
be anti-proliferative in leukemic cells rather than inducing
cell proliferation as shown in our study. This is mainly
related to the choice of purified components being used.
In our study, purified GL polysaccharides were used
whereas purified GL triterpenes such as ganoderic acids
were used in Muller et al. study. From the review of litera-
ture (see Table I), GL polysaccharides have consistently
been shown to have immunological potency and can sup-
press cancer cell growth mainly by activating host's
immune responses. In contrast, the triterpenes exert direct
cytotoxic effect mainly through induction of cell cycle
arrests and apoptosis in cancer cells including human
leukemia, lymphoma and multiple myeloma (HL60,
U937, K562, Blin-1, Nalm-6 and RPMI8226) [14,15];
breast cancer cells MDA-MB-231; and umbilical cord vas-
cular endothelial cells HUVEC [16,17]. These data high-
lighted the importance of the choice of GL components
selected for the study. Standardization of polysaccharidesJournal of Hematology & Oncology 2008, 1:9 http://www.jhoonline.org/content/1/1/9
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Proliferation capacity of THP-1 cells treated with GL-PS after adding GM-CSF/IL-4 Figure 3
Proliferation capacity of THP-1 cells treated with GL-PS after adding GM-CSF/IL-4. (A) Effect of adding GM-CSF/
IL-4 to THP-1 after three-day treatment of GL-PS as determined by XTT proliferation assay. The results represented the mean 
± SD of three representative experiments. *p < 0.05; ** p < 0.01; ***p < 0.001 versus that without GM-CSF/IL-4 added. (B) 
Trypan blue exclusion assay. THP-1 cells after adding either GM-CSF/IL-4 or GL-PS were counted. The results represented the 
mean ± SD of three representative experiments. *p < 0.05; ** p < 0.01; ***p < 0.001 versus that of THP-1 cells.
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Endocytosis of FITC-dextran by THP-1 cells and THP-1 DCs Figure 4
Endocytosis of FITC-dextran by THP-1 cells and THP-1 DCs. (A) Treated DCs were incubated with FITC-dextran for 
1 h at 37°C and then washed for four times. Increase shift in fluorescence intensity (x-axis) was compared with the control, the 
one without FITC-dextran. The result was from one representative experiment of three independent repeats. (B) The 
increase in fluorescence intensity was calculated when compared with that of THP-1 cells alone after normalized with the back-
ground fluorescence, which was from the parallel experiments performed for all cells at 4°C. The results represented the 
mean ± SD from three independent experiments. ** p < 0.01 versus that of THP-1 cells.
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(A) IL-12p70 and (B) IL-10 productions from THP-1 with and without GM-CSF/IL-4 or GL-PS Figure 5
(A) IL-12p70 and (B) IL-10 productions from THP-1 with and without GM-CSF/IL-4 or GL-PS. The culture super-
natants were collected and assayed by ELISA in duplicate. The detection ranges for IL-12 and IL-10 were 31.25–2000 pg/mL 
and 62.5–4000 pg/mL, respectively. The results represented the mean ± SD of four independent experiments for IL-12 and 
three independent experiments for IL-10. ***p < 0.001 versus that of THP-1 cells.
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(A) Allogeneic mixed lymphocyte  reaction of normal mature Mo-DCs (-c-); immature Mo-DCs (-r-); THP-1 cells  alone (-▲-);  THP-1 cells with GL-PS (-❍-); THP-1 DCs (-▪-) and GL-PS  THP-1 DCs (-●-) with CD3+ T cells in the ratio of 1:10 and 1:100 Figure 6
(A) Allogeneic mixed lymphocyte  reaction of normal mature Mo-DCs (-c-); immature Mo-DCs (-r-); THP-1 
cells  alone (-▲-); THP-1 cells with GL-PS (-❍-); THP-1 DCs (-▪-) and GL-PS  THP-1 DCs (-●-) with CD3+ T 
cells in the ratio of 1:10 and 1:100.The optical densities of incorporated BrdU from DC:T co-cultures were normalized 
with that from T cells alone. The results represented one experimental result of three independent experiments. The results 
represented the mean ± SD of three independent experiments. *p < 0.05 versus that of THP-1 cells alone. (B) CD4/CD8 ratio 
of the co-cultured T cells. The co-cultured T cells so harvested were stained with CD4 and CD8 antibody and analyzed with 
flow cytometry. The results represented the mean ± SD of two independent experiments. **p < 0.01 versus that of T cells 
alone.
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and triterpenes contents in the GL products has to be con-
sidered if we would like to extend these in vitro data into
clinical study.
The GL-PS THP-1 DCs so generated morphologically
resembled DCs with upregulated CD11c, HLA-DR, and
costimulation molecules CD40, 80 and 86 (Fig. 2).
Although the expression levels of these molecules were
relatively low when compared with those on normal
monocyte-derived DCs, they showed similar DCs func-
tion of stimulating allogeneic T cells proliferation
responses. They were however immunoregulatory with
the evidence of immature uptake of antigens, the IL-10
production as well as low potency in stimulating alloge-
neic T cell proliferation (Fig. 4, 5, 6). The suppressed T cell
proliferation was believed related to their IL-10 produc-
tion. IL-10 is an immunosuppressive cytokine and renders
T cell stop proliferation even under the challenge of allo-
geneic differences [18]. This is also a mechanism for
leukemic cells to escape from immune surveillance by
dysregulation of immune systems via secretion of IL-10.
Previous studies demonstrated that GL polysaccharides
could induce IL-1 release through the toll-like receptor
(TLR)-4 signaling pathways in murine macrophages [19].
This raised a question that whether other TLRs ligands
could account for the abnormal cellular responses on
monocytic leukemic cells. To test this hypothesis, we also
explored the effect of LPS (a ligand of TLR-4) and
zymosan (a ligand of TLR-2 and dectin-1) on THP-1 DCs
(data not shown). We found that LPS induced more sig-
nificant cell adhesion to the culture plates and caused
more cell death during cell harvesting. This phenomenon
was also reported in previous studies but LPS could not
induce the maturation of the leukemic DCs [8,9]. For the
zymosan treated THP-1, there was no effect in expression
of DC maturation markers; dextran-based endocytosis
and IL-10, IL-12 productions. But we recognized that the
zymosan treated THP-1 DCs with GM-CSF/IL-4 also had
decrease potency in stimulating T cells proliferation. This
implied that the leukemic cells THP-1 might respond to
TLR ligands in different environments such as during
infections and lead to abnormal changes.
Conclusion
In summary, we found that GL polysaccharides could
induce proliferation of monocytic leukemic cells.
Together with GM-CSF/IL-4, GL-PS could induce THP-1
cells to become DCs with significant upregulation of anti-
gen presentation and costimulation molecules expres-
sion. The immuno-potent nature was shown by the
evidences that they retained ability to uptake antigens
with IL-10 productions and decrease in immunostimual-
tory potential for T cell proliferation. Differential response
of monocytic leukemic cells to GL-PS was observed. Our
findings thus suggested that GL polysaccharides or other
TLR ligands might have clinical impact on patients with
monocytic leukemia. Whether GL-PS could induce DCs
differentiation from autologous blast cells to help cancer
patients to reduce cancer cell burden require further in vivo
study for verification.
Materials and methods
Source and preparation of polysaccharides
Purified Ganoderma lucidum polysaccharides (GL-PS) was
kindly provided by Prof. Lin ZB (Department of Pharma-
cology, Peking University Health Science Center, School
of Basic Medical Sciences, Beijing, China). It is a polysac-
charide peptide from GL mycelium with molecular weight
of 584,900 and 17 amino acids. The ratio of polysaccha-
rides to peptides is 93.51%: 6.49%. The polysaccharides
consist of glucose, galactose, arabinose, xylose and man-
nose with molar ratios of
0.793:0.964:2.944:0.167:0.384:7.94 and linked by β-gly-
cosidic linkages [20]. Endotoxin levels in GL-PS were con-
stantly measured by using endotoxin-specific kinetic
chromogenic Limulus Ameobyocyte Lysate (LAL) assay kit
(Pyrochrome®, Associates of Cape Cod, Inc, East Fal-
mouth, MA) with glucan inhibition buffer (Glucashield®,
Associates of Cape Cod) to reconstitute the reagents
according to the manufacturer's instructions. Standard
curves were generated using Control Standard Endotoxin
(CSE) and for better comparison, the LAL reactivity of β-
glucan sample was also compared with that of lipopoly-
saccharide (LPS; Sigma). The endotoxin level of GL-PS
was equivalent to 0.01% of 1 ng lipopolysaccharide, LPS,
E. coli derived, suggesting negligible.
Cell culture of leukemic cells
Leukemic cells, THP-1 and U937 were purchased from
ATCC (Manassas, VA). It was characterized as AML M5.
Cells were cultured in medium consisting of 90% RPMI
1640, 10% FBS, 100 U/mL penicillin, 100 mg/mL strepto-
mycin (Invitrogen, Life Technologies, CA) and main-
tained at 37°C in a humidified atmosphere with 5% CO2.
Generation of leukemic DCs in vitro
The generation of leukemic DCs was modified from that
for normal Mo-DCs as previously described [11,21].
Leukemic cells THP-1 at the density of 1 × 105 per well
were cultured with/without GL-PS (100 μg/mL) in the
presence of GM-CSF (40 ng/mL; Novartis Pharma A6,
Basle, Switzerland) and IL-4 (40 ng/mL; R&D Systems Inc,
Minneapolis, MN) at 37°C under 5% CO2. On Day 3,
90% of the medium was replaced with fresh medium and
cytokines. THP-1 DCs were then harvested on Day 5 and
washed for further assays. For normal monocyte-derived
DCs, mononuclear cells were isolated from buffy coat of
healthy adult donors (Red Cross, Hong Kong SAR, China)
by Ficoll-Paque Plus density gradient (Amersham Bio-Journal of Hematology & Oncology 2008, 1:9 http://www.jhoonline.org/content/1/1/9
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sciences, Uppsala, Sweden). Monocytes were then iso-
lated from PBMCs by positive selection using anti-CD14-
conjugated magnetic microbeads (Miltenyi Biotec, Ber-
gisch Gladbach, Germany). The isolated cells were cul-
tured at a density of 1 × 106  cell/mL in RPMI 1640
medium supplemented with 10% FBS, 50 IU/mL penicil-
lin and 50 IU/mL streptomycin (Invitrogen) with GM-CSF
and IL-4 at 37°C under 5% CO2 for five days. CD3+ T cells
were isolated with the same method except using anti-
CD3-conjugated magnetic microbeads (Miltenyi Biotec.).
The purity of isolated monocytes was consistently > 85%
while that of T cells was consistently > 98% as determined
by Coulter Epics Flow Cytometer (Coulter Corporation,
Miami, FL). Based on flow cytometry analysis, the imma-
ture DCs on Day 5 were 98.3% CD11c+CD1a+ and 99.8%
lineage negative (CD3-, CD14-, CD16-, CD19-, CD20-,
CD56-).
Cell proliferation assay
The effects of GL-PS on cell proliferation were measured
using the Cell Proliferation Kit II XTT assay kit (Roche
Molecular Biochemicals, Mannheim, Germany) accord-
ing to the manufacturer's instructions. Briefly, 5 × 104 cells
per well were grown in flat-bottom 96-well plates in a
final volume of 100 μL culture medium overnight. Cells
were then exposed to GL-PS at different concentrations (1
μg/mL to 1 mg/mL) for 24, 48 and 72 h. After the fixed
time of incubation, 50 μL of the XTT labeling mixture was
added to each well, and incubated for 4 h at 37°C in a
humidified atmosphere with 5% CO2. The formation of
formazan dyes in XTT labeling mixture by metabolically
active cells was detected spectrophotometrically at 450
nm. The cell proliferation was calculated from the OD and
expressed as percentage of negative control. To confirm
the cell proliferation by increase in cell number, trypan
blue exclusion assay was performed with trypan blue stain
(Invitrogen). A minimum of 300 cells were counted under
hemocytometer.
Cell cycle analysis
GL-PS-treated leukemic cells were harvested, washed with
PBS, fixed with ice-cold 70% ethanol and stored at 4°C.
When for assay, the cell suspensions were incubated with
RNase A (100 μg/mL; Sigma) and propidium iodide (4
μg/mL; Sigma) in PBS. Cell cycle phases were then ana-
lyzed with Coulter Epics Flow Cytometer (Beckman Coul-
ter, Inc., Fullerton, CA). The percentage of G1, S and G2/
M were determined with Cylchred Version 1.0.2 (Cardiff
University, Wales, UK). For the expression of proliferating
cell nuclear antigen (PCNA), we stained the cells with Flu-
orescein isothiocyanate (FITC) conjugated PCNA anti-
body (BD PharMingen, San Diego, CA) together with
isotype control FITC-IgGκ (BD PharMingen). The cell
were analyzed with the flow cytometer and the data were
analyzed with WINMDI version 2.8 flow cytometry anal-
ysis software (Purdue University, West Lafayette, IN).
Flow cytometry analysis of DCs
On Day 5, DCs were harvested, washed and labeled with
fluorochrome-conjugated antibodies. After labeling, the
cell suspension was washed and resuspended in 300 μL of
1% paraformaldehyde for flow cytometry. Fluorescein
isothiocyanate (FITC), Phycoerythrin (PE) and Phyco-
erthrin-cyanin 5.1 (PC5)-conjugated isotype controls and
CD14-PE, CD40-FITC, CD80-FITC, CD86-FITC, CD11c-
PE and HLA-DR-PC5 antibodies were purchased from BD
PharMingen. Flow cytometric analysis was performed
with Coulter Epics Flow cytometer (Beckman Coulter)
and analyzed with WINMDI software (Purdue Univer-
sity). To reduce inter-experimental variation, the mean
fluorescence intensities for different CD markers were
normalized with that of RPMI treated negative control as
relative fluorescence intensity.
FITC-dextran endocytosis assay
Leukemic cell-derived and monocyte-derived DCs were
harvested and resuspended in RPMI with 10% FBS. FITC-
dextran (molecular weight 40 kDa; Sigma) was added at a
final concentration of 1 mg/mL. Cells were then incu-
bated at 37°C or 4°C for 1 h. Thereafter, the cells were
washed four times with cold PBS and then analyzed with
flow cytometer.
ELISA assay for cytokines
The supernatants from DCs cultures were collected after
harvesting the cells and stored at -80°C until assayed for
cytokines. The levels of IL-12p70 and IL-10 were then
measured in duplicate with human Duoset® ELISA Kit
(R&D Systems Inc.). The detection ranges for IL-12 and IL-
10 were 31.25–2000 pg/mL and 62.5–4000 pg/mL,
respectively.
Allogeneic mixed lymphocyte reaction
The leukemic cell-derived and monocyte-derived DCs
were irradiated with a gamma-irradiator (Gammacell
1000 Elite, MDS Nordion Inc., Canada) at 30 Gy and co-
cultured at the ratio of 1:10 with 1 × 105  allogeneic
responder CD3+T cells in flat-bottom 96-well microtiter
plates. Bromodeoxyuridine (BrdU) was added into the
wells 16 h before the end of five-day culture. Cell prolifer-
ation during the last 16 h of the five-day culture was quan-
tified by the Cell Proliferation ELISA, BrdU (colorimetric)
kit (Roche Molecular Biochemicals).
Statistical analysis
Comparisons between means were based on nonparamet-
ric Student's t test (2-tailed). For more than two groups,
we compared the means with one-way ANOVA. The dif-
ference was statistically significant when p < 0.05.Publish with BioMed Central    and   every 
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